ClinicalTrials.gg
CompletedNCT06746311Updated Nov 2, 2026

This is a Phase 1 Study in Which Healthy Volunteers and Participants With Chronic HBV Infection Will be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

A Phase 1 interventional study of HT-101 and HT-101 in Chronic Hepatitis b, sponsored by Suzhou HepaThera Biotech Co., Ltd.. Completed at 7 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Suzhou HepaThera Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Nov 2022, registered Dec 2024).
Updated Nov 2, 2026Interventions changedTitle changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Enrollment
188th of 273
82 · median 120
Started
2022
with 23 others
Phase 1
50 of 375
16 open now
Registered
305th of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 188th largest by enrollment of the 273 interventional ones that give a count, is one of 24 that started in 2022, is one of 50 in phase 1, and was the 305th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

Phase 1 Study of HT-101 in Healthy Subjects and Patients With Chronic Hepatitis B The trial consisted of two components. Part A involved a single ascending dose study where healthy participants were administered one dose of HT-101 or placebo subcutaneously (SC). Part B involved a multiple ascending dose study where participants with chronic hepatitis B virus infection were administered two dose of HT-101 or placebo every 4 weeks subcutaneously (SC).

03

Conditions studied

  • Chronic Hepatitis b

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Subjects were eligible for inclusion into the study if they met each of the following criteria:

Part A SAD: Healthy Participant

  • Male participants weighed ≥ 50.0 kg, female participants weighed ≥ 45.0 kg;
  • Participants who promise having used effective for at least 1 month before screening, and have no plans for pregnancy or donating sperm or eggs, and will voluntarily use effective physical means of contraception (including the partner) during the study and for 3 months after the end of the study;

Part B MAD: Patient with CHB

  • Male subjects weighed ≥ 50.0 kg, female subjects weighed ≥ 45.0 kg, with a (BMI) between 19.0 and 28.0 kg/m\^2 (inclusive);
  • Chronic infection for >/= 6 months;
  • The quantitation level of HBsAg was > 200 IU/mL and \< 5000 IU/mL; The quantitation level of HBV DNA \< 2×10\^4 IU/mL;
  • Subjects promised to use effective contraception for at least 1 month before screening, and have no fertility, donate sperm or eggs and voluntarily take highly effective physical contraception (including partners) during the trial and within 3 months after the end of the trial;

Exclusion Criteria:Subjects were excluded from the study if one or more of the following criteria were applicable

  • Participants with history of drug allergy or specific allergy;
  • Participants who had psychiatric conditions or diseases in cardiovascular, respiratory, endocrine, kidney, liver, digestive tract, skin, immune, blood, nerve and other systems;
  • Participants with history of active pathological bleeding, or bleeding tendency;
  • Participants with abnormal results of physical examination, vital sign examination, examination, laboratory test in the screening period which were judged as by clinicians;
  • Participants with significant liver fibrosis or cirrhosis;
  • Participants with symptoms or a history of hepatic decompensation;
  • Participants with a history or suspected risk of liver cancerr;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Part A:HT-101 or placebo

    Single ascending Dose of HT-101 or placebo in Healthy participants subcustaneously.

    Drug: HT-101 · Drug: Placebo

  • Experimental
    Part B: HT-101 or placebo

    Multiple Ascending Dose of HT-101 or placebo in patients with Chronic hepatitis B virus subcustaneously.

    Drug: HT-101 · Drug: Placebo

Interventions

  • DrugHT-101

    Single dose of HT-101 administered subcutaneously.

  • DrugHT-101

    Multiple dose of HT-101 administered subcutaneously.

  • DrugPlacebo

    Placebo, containing no active ingredient, administered subcutaneouly

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Clinically significant abnormalities

    Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v5.0.

    Time frame: From enrollment to the end of treatment at 24 weeks

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Cmax of HT-101 and its metabolite in plasma. First administration (Healty participants and Patients with CHB): Predose 0.5 hours; Postdose 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours. Second administration (Patients with CHB): Predose 0.5 hours; postdose 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours.

    Time frame: From predose 0.5 hours to postdose 48 hours.

  2. Time to Reach Maximum Plasma Concentration (Tmax)

    Tmax of HT-101 and its metabolite in plasma. First administration (Healty participants and Patients with CHB): Predose 0.5 hours; Postdose 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours. Second administration (Patients with CHB): Predose 0.5 hours; postdose 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours.

    Time frame: From predose 0.5 hours to postdose 48 hours.

  3. Area Under the Plasma Concentration Versus Time Curve (AUC)

    AUC of HT-101 and its metabolite from time 0 to last measurable time. First administration (Healty participants and Patients with CHB): Predose 0.5 hours; Postdose 0.5 hours,1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours. Second administration (Patients with CHB): Predose 0.5 hours; postdose 0.5 hours,1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours.

    Time frame: From predose 0.5 hours to postdose 48 hours.

  4. Apparent Terminal Elimination Half-life (T1/2)

    T1/2 of HT-101 in plasma. First administration (Healty participants and Patients with CHB): Predose 0.5 hours; Postdose 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours. Second administration (Patients with CHB): Predose 0.5 hours; postdose 0.5 hours, 1hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours.

    Time frame: From predose 0.5 hours to postdose 48 hours.

  5. Apparent Plasma Clearance (CL/F)

    CL/F of HT-101 in plasma. First administration (Healty participants and Patients with CHB): Predose 0.5 hours; Postdose 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours. Second administration (Patients with CHB): Predose 0.5 hours; postdose 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours.

    Time frame: From predose 0.5 hours to postdose 48 hours.

  6. apparent volume of distribution(Vd/F)

    Vd/F of HT-101. First administration (Healty participants and Patients with CHB): Predose 0.5 hours; Postdose 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours. Second administration (Patients with CHB): Predose 0.5 hours; postdose 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours and 48 hours.

    Time frame: From predose 0.5 hours to postdose 48 hours.

  7. Maximum Change of Serum HBsAg From Baseline

    Maximum change of serum HBsAg from Day 1 until 24 weeks post last dose (negative values mean reductions from baseline, positive values mean increased from baseline)

    Time frame: Up to 24 weeks

  8. Maximum Change of Serum HBV DNA From Baseline

    Maximum change of serum HBV DNA from Day 1 until 24 weeks (negative values mean reductions from baseline, positive values mean increased from baseline).

    Time frame: Up to 24 weeks

  9. Number of participants with HBeAg Loss

    For HBeAg-positive Participants: Number of Subjects With HBeAg Loss

    Time frame: Up to 24 weeks

07

Study locations

7 sites
  • Beijing Ditan Hospital Capital Medical University
    Beijing, Beijing Municipality 100015, China
  • Beijing Friendship Hospital
    Beijing, Beijing Municipality 100050, China
  • Nanfang Hospital
    Guangzhou, Guangdong 510515, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221132, China
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Yanbian University Hospital
    Yanji, Jilin 133000, China
  • Shanghai Public Health Clinical Center
    Shanghai, Shanghai Municipality 200083, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in May 2024, 17 months.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 17 months is above that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 24, 2024
StartActual
Nov 22, 2022
Primary completionActual
May 13, 2024
CompletionActual
Jun 17, 2024
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (3 China)
  • Beijing Ditan Hospital Capital Medical University · Beijing, China
  • Beijing Friendship Hospital · Beijing, China
  • Shanghai Public Health Clinical Center · Shanghai, China
Show 3 removed
  • Beijing Ditan Hospital Capital Medical University · Beijing, China
  • Beijing Friendship Hospital · Beijing, China
  • Shanghai Public Health Clinical Center · Shanghai, China
Nov 2, 2026
Interventions
Arm changed Part A→Part A:HT-101 or placebo; Part B→Part B: HT-101 or placebo
Nov 2, 2026
Title
This is a Phase 1 Study in Which Healthy Volunteers and Participants withWith Chronic HBV Infection Will Receive HT-101 or Placebo and Will Bebe Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    3 sites added, 3 sites removed
    Show 3 added (3 China)
    • Beijing Ditan Hospital Capital Medical University · Beijing, China
    • Beijing Friendship Hospital · Beijing, China
    • Shanghai Public Health Clinical Center · Shanghai, China
    Show 3 removed
    • Beijing Ditan Hospital Capital Medical University · Beijing, China
    • Beijing Friendship Hospital · Beijing, China
    • Shanghai Public Health Clinical Center · Shanghai, China
    Interventions Arm changed Part A→Part A:HT-101 or placebo; Part B→Part B: HT-101 or placebo
    Title This is a Phase 1 Study in Which Healthy Volunteers and Participants withWith Chronic HBV Infection Will Receive HT-101 or Placebo and Will Bebe Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity
    + 2 other changes: index terms and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06746311
Lead sponsor
Suzhou HepaThera Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Nov 22, 2022
Primary completion
May 13, 2024
Completion
Jun 17, 2024
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HT-101

Start the discussion